Weight Loss With SGLT2 Inhibitors, Semaglutide, and Transcranial Magnetic Stimulation in Type 2 Diabetes and Obesity
Obesity · 2026
DOI: 10.1002/oby.70105 ↗Kurz gefasst
Klinische Studie in der Zeitschrift Obesity, 2026. Verfasst von Anna Ferrulli und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Nutrition and Metabolic Diseases, IRCCS MultiMedica, Milan, Italy. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Hypoglycemic Agents, Obesity. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 19 Literaturangaben. Gefördert von: Ricerca Corrente-IRCCS MultiMedica, Italian Ministry of Health, Ministero della Salute.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Objective
This study compared the efficacy of a GLP‐1 receptor agonist (GLP1‐RA) (semaglutide, 0.5 mg/week), sodium‐glucose cotransporter‐2 inhibitors (SGLT2i), and repetitive transcranial magnetic stimulation (rTMS), a new emerging treatment for obesity, in reducing body weight (BW) after 1 year in patients with obesity and type 2 diabetes (T2D).
Methods
We included 40 patients with T2D treated with a SGLT2i, 37 patients with T2D treated with the GLP1‐RA semaglutide, and 30 patients treated with rTMS in this retrospective comparative analysis. rTMS was administered three times per week for 5 weeks. All patients received dietary advice about moderate caloric restriction (−300 kcal/day).
Results
After 12 months the weight loss with rTMS (−8.2 ± 1.0 kg) was not significantly different from that with semaglutide (−5.7 ± 0.9 kg). Weight loss with SGLT2i (−2.0 ± 0.7 kg) was significantly less than with both semaglutide ( p = 0.01) and rTMS ( p < 0.0001). Individuals receiving SGLT2i therapy experienced weight regain from month 6 to month 12, while BW declined progressively in patients treated with semaglutide and rTMS.
Conclusions
Treatment with rTMS produced a comparable reduction in BW to that observed with the GLP1‐RA semaglutide (at the dose of 0.5 mg/week) and represents a promising intervention for the treatment of obesity and T2D. Trial Registration ClinicalTrials.gov identifier: NCT03009695
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology, Nutrition and Metabolic Diseases, IRCCS MultiMedica, Milan, Italy.
- Department of Biomedical Sciences for Health, University of Milan, Milan, Italy.
- Division of Cardiology, IRCCS MultiMedica, Milan, Italy.
- Division of Diabetes, UT Health San Antonio, San Antonio, Texas, USA.
- Texas Diabetes Institute, San Antonio, Texas, USA.
ORCID-Profile: Livio Luzi
Förderung
- Ricerca Corrente-IRCCS MultiMedica
- Italian Ministry of Health
- Ministero della Salute
Zitieren
APA
Ferrulli, A., Senesi, P., Sonaglioni, A., Cannavaro, D., Massarini, S., Macrì, C., Cipponeri, E., DeFronzo, R. A., & Luzi, L. (2026). Weight Loss With SGLT2 Inhibitors, Semaglutide, and Transcranial Magnetic Stimulation in Type 2 Diabetes and Obesity. Obesity. https://doi.org/10.1002/oby.70105
Vancouver
Ferrulli A, Senesi P, Sonaglioni A, Cannavaro D, Massarini S, Macrì C, et al. Weight Loss With SGLT2 Inhibitors, Semaglutide, and Transcranial Magnetic Stimulation in Type 2 Diabetes and Obesity. Obesity. 2026. doi:10.1002/oby.70105
BibTeX
@article{Ferrulli2026,
author = {Ferrulli, Anna and Senesi, Pamela and Sonaglioni, Andrea and Cannavaro, Daniele and Massarini, Stefano and Macrì, Concetta and Cipponeri, Elisa and DeFronzo, Ralph A and Luzi, Livio},
title = {Weight Loss With SGLT2 Inhibitors, Semaglutide, and Transcranial Magnetic Stimulation in Type 2 Diabetes and Obesity},
journal = {Obesity},
year = {2026},
doi = {10.1002/oby.70105}
}
EUVIMED